1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional) is sponsored by National Cancer Institute (NCI). This Notice of Funding Opportunity (NOFO) solicits research projects that investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy.
The goal is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the opportunity page linked on this listing to help you evaluate fit faster.
Opportunity Listing - Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional) Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional) Agency: National Institutes of Health Assistance Listings: 93. 395 -- Cancer Treatment Research Last Updated: May 13, 2026 View version history on Grants.
gov Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits research projects that investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy.
The goal of the Precision Approaches in Radiation Synthetic Combinations ( PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments. Early synthetic lethality–based therapeutic strategies in oncology primarily focused on targeting fixed mutations or genomic abnormalities.
More recently, however, it has become clear that clinical benefit is often determined by context-dependent vulnerabilities arising from the intrinsic mutational landscape and adaptive tumor responses.
For-profit organizations other than small businesses Private institutions of higher education Public and state institutions of higher education Independent school districts Nonprofits non-higher education without 501(c)(3) Nonprofits non-higher education with 501(c)(3) Other Native American tribal organizations City or township governments Special district governments Federally recognized Native American tribal governments Public and Indian housing authorities Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Grantor contact information Email: pairsresearchgrants@nih. gov Email: pairsresearchgrants@nih. gov No documents are currently available.
Link to additional information Estimated Application Due Date : Estimated Due Date Description : Estimated Project Start Date : Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: For-profit organizations other than small businesses, small businesses, and other eligible entities (universities are typically eligible for NCI grants). Confirm the full requirements in the official notice before applying.
The published deadline was November 11, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional) is funded by National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
On May 21, 2026, the National Cancer Institute posted RFA-CA-27-006, RFA-CA-27-007, and RFA-CA-27-008 — the three competitive renewals for the NCI Community Oncology Research Program. Combined FY 2027 commitments reach $147.5 million across roughly 57 awards: $74.5 million for up to 7 Research Bases, $73 million for up to 50 Community and Academic Community Sites. Pre-application webinars run June 16-18 this week. Applications are due August 18, 2026 with six-year project periods. For community hospitals, oncology consortia, and NCI-designated cancer centers, this is the single largest cancer clinical-trials infrastructure decision NCI makes until 2033.
Read articleRFA-RM-27-008 funds one or two U24 centers to sequence 6,000-10,000 pediatric samples a year for Gabriella Miller Kids First. Due January 8, 2027. Who can compete.
Read articleProp. 38, the $8.4 billion immunology research bond, led 56% to 44% the morning after the November 3, 2026 election. Here is what the statute says about who can get the grant money, the 20% indirect cap, and the timeline.
Read article